Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma | Cataract and Other Lens Disorders | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Munier  FL, Gaillard  M-C, Balmer  A,  et al.  Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.  Br J Ophthalmol. 2012;96(8):1078-1083.PubMedGoogle ScholarCrossref
Shields  CL, Manjandavida  FP, Arepalli  S, Kaliki  S, Lally  SE, Shields  JA.  Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.  JAMA Ophthalmol. 2014;132(3):319-325.PubMedGoogle ScholarCrossref
Ghassemi  F, Shields  CL.  Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.  Arch Ophthalmol. 2012;130(10):1268-1271.PubMedGoogle ScholarCrossref
Francis  JH, Schaiquevich  P, Buitrago  E,  et al.  Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.  Ophthalmology. 2014;121(9):1810-1817.PubMedGoogle ScholarCrossref
Ghassemi  F, Amoli  FA.  Pathological findings in enucleated eyes after intravitreal melphalan injection.  Int Ophthalmol. 2014;34(3):533-540.PubMedGoogle ScholarCrossref
Shimoda  Y, Hamano  R, Ishihara  K,  et al.  Effects of intraocular irrigation with melphalan on rabbit retinas during vitrectomy.  Graefes Arch Clin Exp Ophthalmol. 2008;246(4):501-508.PubMedGoogle ScholarCrossref
Ueda  M, Tanabe  J, Inomata  M, Kaneko  A, Kimura  T.  Study on conservative treatment of retinoblastoma—effect of intravitreal injection of melphalan on the rabbit retina [in Japanese].  Nihon Ganka Gakkai Zasshi. 1995;99(11):1230-1235.PubMedGoogle Scholar
Francis  JH, Abramson  DH, Gaillard  M-C, Marr  BP, Beck-Popovic  M, Munier  FL.  The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan.  Ophthalmology. 2015;122(6):1173-1179.PubMedGoogle ScholarCrossref
Zinkernagel  MS, Schorno  P, Ebneter  A, Wolf  S.  Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant.  Invest Ophthalmol Vis Sci. 2014;56(3):1894-1900.PubMedGoogle ScholarCrossref
Sato  T, Emi  K, Ikeda  T,  et al.  Severe intraocular inflammation after intravitreal injection of bevacizumab.  Ophthalmology. 2010;117(3):512-516.PubMedGoogle ScholarCrossref
Bayar  SA, Altinors  DD, Kucukerdonmez  C, Akova  YA.  Severe corneal changes following intravitreal injection of bevacizumab.  Ocul Immunol Inflamm. 2010;18(4):268-274.PubMedGoogle ScholarCrossref
Meyer  CH, Rodrigues  EB, Michels  S,  et al.  Incidence of damage to the crystalline lens during intravitreal injections.  J Ocul Pharmacol Ther. 2010;26(5):491-495.PubMedGoogle ScholarCrossref
Jørgensen  JS, Kemp  H, Sørensen  TL.  Identification of foreign bodies on the ocular surface after uneventful intravitreal injections.  Acta Ophthalmol. 2012;90(8):e646-e647. doi:10.1111/j.1755-3768.2012.02405.x. PubMedGoogle ScholarCrossref
Suzuki  S, Aihara  Y, Fujiwara  M, Sano  S, Kaneko  A.  Intravitreal injection of melphalan for intraocular retinoblastoma.  Jpn J Ophthalmol. 2015;59(3):164-172.PubMedGoogle ScholarCrossref
Smith  SJ, Smith  BD, Mohney  BG.  Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.  Br J Ophthalmol. 2014;98(3):292-297.PubMedGoogle ScholarCrossref
Brief Report
December 2015

Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma

Author Affiliations
  • 1Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Department of Ophthalmology, Weill Cornell Medical College, New York, New York
  • 3Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York
JAMA Ophthalmol. 2015;133(12):1459-1463. doi:10.1001/jamaophthalmol.2015.3119

Importance  Intravitreous injections of melphalan hydrochloride are increasingly used in the treatment of vitreous seeding of retinoblastoma. Although this technique can save eyes otherwise destined for enucleation, ocular salvage may be accompanied by local toxic effects. Posterior segment toxic effects in this context are well established. This report describes the toxic effects on the anterior segment following intravitreous administration of melphalan.

Observations  Our clinic cohort included 76 patients who received intravitreous injections of melphalan at Memorial Sloan Kettering Cancer Center from September 12, 2012, through April 15, 2015; data analysis was performed from April 15 through May 15, 2015. We report a series of 5 patients from this cohort who developed anterior segment toxic effects. These abnormalities were found at the injection site or within the meridian of the injection and included a traumatic cataract following an injection at an outside hospital, iris depigmentation and thinning, iris recession with retinal necrosis and hypotony, a filtering conjunctival bleb, and focal scleromalacia with localized pigmentation.

Conclusions and Relevance  Intravitreous injection of melphalan may result in toxic effects on the anterior segment of the eye, in addition to retinal abnormalities, and appears to be more common in the meridian of the injection where the drug concentration is highest.